Clinical effect analysis of albumin-binding paclitaxel combined with nedaplatin in the treatment of advanced esophageal cancer
Objective To analyze the effect of albumin-binding paclitaxel combined with nedaplatin in the treatment of advanced esophageal cancer.Methods 66 patients with histologically proven unresectable or postoperative recurrent or metastatic advanced esophageal cancer were divided into a control group and an observation group by random number table method,each with 33 cases.The control group was treated with paclitaxel and cisplatin,while the observation group was treated with albumin-binding paclitaxel and nedaplatin.Both groups were compared in terms of clinical efficacy,quality of life score,levels of serum tumor markers[cancer antigen 125(CA125),cancer antigen 19-9(CA19-9),squamous cell carcinoma antigen(SCC),carcinoembryonic antigen(CEA)]and the occurrence of adverse reactions.Results The objective response rate(ORR)of the observation group was 60.61%,which was higher than 36.36%of the control group(P<0.05).There was no difference in disease control rate(DCR)between the two groups(P>0.05).The scores of physical function,psychological function,social function and material life in the observation group were(88.80±4.50),(89.05±4.05),(88.20±3.50)and(87.80±5.02)points,which were higher than(73.20±3.80),(73.60±3.50),(72.60±3.30)and(71.50±3.50)points of the control group(P<0.05).After treatment,the levels of CA125,CA19-9,SCC and CEA in both groups were lower than those before treatment;the observation group had CA125 of(8.08±1.60)U/ml,CA19-9 of(8.99±1.22)U/ml,SCC of(1.08±0.20)μg/L and CEA of(1.47±0.14)ng/ml,which were lower than(9.33±1.45)U/ml,(10.30±1.33)U/ml,(1.67±0.25)μg/L and(1.72±0.18)ng/ml in the control group(P<0.05).The incidence of thrombocytopenia,neutropenia,nausea and vomiting,myalgia,arthralgia and peripheral neuropathy in the observation group was similar to that in the control group(P>0.05).Conclusion The treatment of albumin-binding paclitaxel combined with nedaplatin in patients with advanced esophageal cancer can improve the therapeutic effect,promote the improvement of serum tumor markers and quality of life of patients without increasing the adverse reactions.
万方数据
维普
